IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders.

In the adjusted regression analysis including both favourable SNPs, IL28B 12979860-CC maintained is significant association with SVR12 in the whole cohort and a trend towards significance was observed also in the subgroup of patients naïve, interruption due to SEs, virological breakthrough and relapsers, whereas the association between rs8099917-TT and SVR12 disappeared in all treatment groups (Table 4 ).

also in 2,760 other papers